LncRNA-ATB Promotes Trastuzumab Resistance and Invasion-metastasis Cascade in Breast Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Apr 15

PMID 25871474

Citations 178

Authors

Sheng-Jia Shi

Li-Juan Wang

Bo Yu

Yun-Hui Li

Yong Jin

Xiao-Zhong Bai

Affiliations

Soon will be listed here.

Abstract

Trastuzumab resistance is leading cause of mortality in HER2-positive breast cancers, and the role of TGF-β-induced epithelial-mesenchymal transition (EMT) in trastuzumab resistance is well established, but the involvement of lncRNAs in trastuzumab resistance is still unknown. Here, we generated trastuzumab-resistant breast cancer cells with increased invasiveness compared with parental cells, and observed robust epithelial-mesenchymal transition (EMT) and consistently elevated TGF-β signaling in these cells. We identified long noncoding RNA activated by TGF-β (lnc-ATB) was the most remarkably upregulated lncRNA in TR SKBR-3 cells and the tissues of TR breast cancer patients. We found that lnc-ATB could promote trastuzumab resistance and invasion-metastasis cascade in breast cancer by competitively biding miR-200c, up-regulating ZEB1 and ZNF-217, and then inducing EMT. In addition, we also found that the high level of lnc-ATB was correlated with trastuzumab resistance of breast cancer patients. Thus, these findings suggest that lncRNA-ATB, a mediator of TGF-β signaling, could predispose breast cancer patients to EMT and trastuzumab resistance.

Citing Articles

Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes.

Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X Cancer Cell Int. 2025; 25(1):77.

PMID: 40045297 PMC: 11881339. DOI: 10.1186/s12935-025-03680-7.

Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.

Insights and implications for transcriptomic analysis of heat stress-induced intestinal inflammation in pigs.

Yu Z, Yong Y, Liu X, Ma X, Abd El-Aty A, Li L BMC Genomics. 2024; 25(1):1110.

PMID: 39563245 PMC: 11577645. DOI: 10.1186/s12864-024-10928-5.

Molecular Mechanism of lncRNAs in Regulation of Breast Cancer Metastasis; a Comprehensive Review.

Ahmadi S, Yazdi F, Khastar S, Kaur I, Ahmed M, Kumar A Cell Biochem Biophys. 2024; 83(1):229-245.

PMID: 39367197 DOI: 10.1007/s12013-024-01535-y.

MicroRNA as Key Players in Hepatocellular Carcinoma: Insights into Their Role in Metastasis.

Saadh M, Hussain Q, Alazzawi T, Fahdil A, Athab Z, Yarmukhamedov B Biochem Genet. 2024; .

PMID: 39103713 DOI: 10.1007/s10528-024-10897-0.

References

Hilmarsdottir B, Briem E, Bergthorsson J, Magnusson M, Gudjonsson T . Functional Role of the microRNA-200 Family in Breast Morphogenesis and Neoplasia. Genes (Basel). 2014; 5(3):804-20. PMC: 4198932. DOI: 10.3390/genes5030804. View

Akhurst R, Hata A . Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012; 11(10):790-811. PMC: 3520610. DOI: 10.1038/nrd3810. View

Su X, Malouf G, Chen Y, Zhang J, Yao H, Valero V . Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget. 2014; 5(20):9864-76. PMC: 4259443. DOI: 10.18632/oncotarget.2454. View

Bai W, Ye X, Zhang M, Zhu H, Xi W, Huang X . MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 2014; 135(6):1356-68. DOI: 10.1002/ijc.28782. View

Gajria D, Chandarlapaty S . HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011; 11(2):263-75. PMC: 3092522. DOI: 10.1586/era.10.226. View

Yuan J, Yang F, Wang F, Ma J, Guo Y, Tao Q . A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014; 25(5):666-81. DOI: 10.1016/j.ccr.2014.03.010. View

Zhang S, Huang W, Li P, Guo H, Poh S, Brady S . Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011; 17(4):461-9. PMC: 3877934. DOI: 10.1038/nm.2309. View

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S . A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9(6):582-9. PMC: 2396950. DOI: 10.1038/embor.2008.74. View

Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22. DOI: 10.1007/978-0-387-74039-3_1. View

10.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

11.

Polyak K, Weinberg R . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-73. DOI: 10.1038/nrc2620. View

12.

Klymkowsky M, Savagner P . Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol. 2009; 174(5):1588-93. PMC: 2671246. DOI: 10.2353/ajpath.2009.080545. View

13.

Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham D . HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000; 92(24):1991-8. DOI: 10.1093/jnci/92.24.1991. View

14.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

15.

Joshi J, Brown N, Griner S, Nahta R . Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol. 2011; 82(9):1090-9. PMC: 3191232. DOI: 10.1016/j.bcp.2011.07.082. View

16.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

17.

Niikura N, Liu J, Hayashi N, Mittendorf E, Gong Y, Palla S . Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2011; 30(6):593-9. PMC: 3295557. DOI: 10.1200/JCO.2010.33.8889. View

18.

Narayan M, Wilken J, Harris L, Baron A, Kimbler K, Maihle N . Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 2009; 69(6):2191-4. DOI: 10.1158/0008-5472.CAN-08-1056. View

19.

Seton-Rogers S, Lu Y, Hines L, Koundinya M, LaBaer J, Muthuswamy S . Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A. 2004; 101(5):1257-62. PMC: 337040. DOI: 10.1073/pnas.0308090100. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View